Moving towards disease modification in inflammatory bowel disease therapy

Current Opinion in Gastroenterology

Volumn 29, Issue 4, 2013, Pages 397-404

  Allen, Patrick B ^a   Peyrin Biroulet, Laurent ^b  

^a ULSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

deep remission; poor prognostic indicators in IBD; treat beyond symptoms

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; VEDOLIZUMAB;

BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISABILITY; DISEASE COURSE; DISEASE DURATION; EARLY INTERVENTION; ENVIRONMENTAL FACTOR; FUNCTIONAL STATUS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENT CELL; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MULTICENTER STUDY (TOPIC); PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITATIVE RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; TREATMENT FAILURE; ULCERATIVE COLITIS; WORLD HEALTH ORGANIZATION;

ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879894997     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283622914     Document Type: Review

References (63)

1. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn'sdisease in a population-based cohortfrom Cardiff (1986-2003): a study ofchanges in medical treatment and surgical resection rates. Gut 2010; 59:1200-1206.
2. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60:930-936.
3. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107:1879-1887.
4. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135:1493-1499.
5. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroentero-logy 2009; 137:1250-1260.
6. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumabdoseintensification inCrohn'sdisease: a systematicreview. Am J Gastroenterol 2011; 106:674-684.
7. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104:760-767.
8. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:870-879.
9. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011; 60:1178-1181.
10. Filippi J, Allen PB, Hebuterne X, Peyrin-Biroulet L. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011; 12:1440-1447.
11. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5:477-483.
12. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61:241-247.
13. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010; 16:15-22.
14. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:438-444.
15. Pariente B, Peyrin-Biroulet L, Cohen L, et al. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentgenol 2011; 197:42-49; Epub 2011/06/28.
16. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17: 1415-1422.
17. Romkens TE, Kampschreur MT, Drenth JP, et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18:2190-2198.
18. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastro-enterol Hepatol 2010; 7:15-29.
19. Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1428-1435.
20. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395.
21. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe UC: the UC SUCCESS trial [abstract 835]. Presented at DDW 2011, Chicago, IL; 2011.
22. Zallot C, Peyrin-Biroulet L. Clinical riskfactors for complicated disease: how reliable are they? Digest Dis 2012; 30 (Suppl 3):67-72.
23. Colombel JF, Rutgeerts P, Sandborn WJ, et al. Deep remission predicts long term outcome for adalimumab treated patients with Crohn's disease: data from EXTEND. Gut 2010; 132:52-65.
24. Sandborn WJ, Colombel JF, Lomax K, et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: data from EXTEND. Gut 2011; 60:A136-A137.
25. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesentericfat as asource of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61:78-85.
26. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013; 15:315.
27. Casellas F, Lopez-Vivancos J, Vergara M, Malagelada J. Impact of inflammatory bowel disease on health-related quality of life. Digest Dis 1999; 17:208-218.
28. World Health Organisation. International classification of functioning, dis-ability and health (ICF). 2001:; www.who.int/classifications/icf/en/.
29. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139:1147-1155.
30. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14:706-720.
31. Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis: changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum 1982; 25:540-549.
32. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105:1574-1582.
33. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7:213-221.
34. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18:425-431.
35. Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the paris definition ofearlyCrohn's diseasefor disease-modification trials: resultsof an international expert opinion process. Am J Gastroenterol 2012; 107:1770-1776.
36. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn'sdisease: results of a Norwegian population-based ten-yearfollow-up study. Clin Gastroenterol Hepatol 2007; 5:1430-1438.
37. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38-45.
38. Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol 2011; 7:652-659.
39. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-2028.
40. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99:2376-2384.
41. Vasiliauskas EA, Kam LY, Karp LC, et al. Markerantibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47:487-496.
42. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394-1403.
43. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predictdisease progression. Am JGastroenterol 2006; 101:360-367.
44. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012; 18:1340-1355.
45. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123:679-688.
46. Ahmad T, Armuzzi A, Bunce M, et al. The molecularclassification oftheclinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854-866.
47. Weersma RK, Stokkers PC, Cleynen I, et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol 2009; 104:630-638.
48. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7:972-980.
49. Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121:4170-4179.
50. Cleynen I, Gonzalez JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2012. [Epub 25 December 2012].
51. Jung C, Colombel JF, Lemann M, et al. Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PloS One 2012; 7:e52223.
52. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4:63-101.
53. Peyrin Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013. (in press).
54. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012; 61:918-932.
55. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patientswith moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-1141.
56. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519-1528.
57. Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 study of CP-690, 550, an oral Janus kinase inhibitor, in active ulcerative colitis [Abstract 594]. DDW 2011.
58. Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 randomized study of CP-690, 550, an oral Janus kinase inhibitor, in active Crohn's disease [Abstract 745]. Chicago IL: DDW; 2011.
59. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507.
60. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370-1377.
61. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141:1621-1628.
62. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH Study. Am J Gastroenterol 2013; 108:99-105.
63. Peyrin Biroulet L. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDS): the missing term in the literature. Am J Gastroenterol 2013. (in press).